BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26011734)

  • 1. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways.
    Lichner Z; Ding Q; Samaan S; Saleh C; Nasser A; Al-Haddad S; Samuel JN; Fleshner NE; Stephan C; Jung K; Yousef GM
    J Pathol; 2015 Oct; 237(2):226-37. PubMed ID: 26011734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of microRNAs 371 and 34a in androgen receptor control influencing prostate cancer behavior.
    Leite KR; Morais DR; Florez MG; Reis ST; Iscaife A; Viana N; Moura CM; Silva IA; Katz BS; Pontes J; Nesrallah A; Srougi M
    Urol Oncol; 2015 Jun; 33(6):267.e15-22. PubMed ID: 25920548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
    Jalava SE; Urbanucci A; Latonen L; Waltering KK; Sahu B; Jänne OA; Seppälä J; Lähdesmäki H; Tammela TL; Visakorpi T
    Oncogene; 2012 Oct; 31(41):4460-71. PubMed ID: 22266859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
    Östling P; Leivonen SK; Aakula A; Kohonen P; Mäkelä R; Hagman Z; Edsjö A; Kangaspeska S; Edgren H; Nicorici D; Bjartell A; Ceder Y; Perälä M; Kallioniemi O
    Cancer Res; 2011 Mar; 71(5):1956-67. PubMed ID: 21343391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kallikreins are involved in an miRNA network that contributes to prostate cancer progression.
    Samaan S; Lichner Z; Ding Q; Saleh C; Samuel J; Streutker C; Yousef GM
    Biol Chem; 2014 Sep; 395(9):991-1001. PubMed ID: 25153383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1.
    Xu B; Huang Y; Niu X; Tao T; Jiang L; Tong N; Chen S; Liu N; Zhu W; Chen M
    Prostate; 2015 Dec; 75(16):1896-903. PubMed ID: 26306811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
    Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
    Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells.
    Meng D; Yang S; Wan X; Zhang Y; Huang W; Zhao P; Li T; Wang L; Huang Y; Li T; Li Y
    Int J Biochem Cell Biol; 2016 Apr; 73():30-40. PubMed ID: 26827675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis.
    Zhu Z; Wen Y; Xuan C; Chen Q; Xiang Q; Wang J; Liu Y; Luo L; Zhao S; Deng Y; Zhao Z
    FEBS Open Bio; 2020 Apr; 10(4):674-688. PubMed ID: 32027093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway.
    Lin L; Jiang H; Huang M; Hou X; Sun X; Jiang X; Dong X; Sun X; Zhou B; Qiao H
    Oncol Rep; 2015 Aug; 34(2):663-72. PubMed ID: 26035691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
    Fendler A; Jung M; Stephan C; Honey RJ; Stewart RJ; Pace KT; Erbersdobler A; Samaan S; Jung K; Yousef GM
    Int J Oncol; 2011 Nov; 39(5):1183-92. PubMed ID: 21769427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer.
    Tsuchiyama K; Ito H; Taga M; Naganuma S; Oshinoya Y; Nagano K; Yokoyama O; Itoh H
    Prostate; 2013 Jun; 73(8):827-34. PubMed ID: 23184537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer.
    Shukla KK; Misra S; Pareek P; Mishra V; Singhal B; Sharma P
    Urol Oncol; 2017 Mar; 35(3):92-101. PubMed ID: 27890424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
    Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
    Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.
    Larne O; Hagman Z; Lilja H; Bjartell A; Edsjö A; Ceder Y
    Carcinogenesis; 2015 Aug; 36(8):858-66. PubMed ID: 25969144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.
    Fuse M; Kojima S; Enokida H; Chiyomaru T; Yoshino H; Nohata N; Kinoshita T; Sakamoto S; Naya Y; Nakagawa M; Ichikawa T; Seki N
    J Hum Genet; 2012 Nov; 57(11):691-9. PubMed ID: 22854542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis.
    Leite KR; Sousa-Canavez JM; Reis ST; Tomiyama AH; Camara-Lopes LH; Sañudo A; Antunes AA; Srougi M
    Urol Oncol; 2011; 29(3):265-9. PubMed ID: 19372056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer.
    Ottman R; Levy J; Grizzle WE; Chakrabarti R
    Oncotarget; 2016 Nov; 7(45):73739-73753. PubMed ID: 27650539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-539 inhibits prostate cancer progression by directly targeting SPAG5.
    Zhang H; Li S; Yang X; Qiao B; Zhang Z; Xu Y
    J Exp Clin Cancer Res; 2016 Apr; 35():60. PubMed ID: 27037000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.